$AVIR News

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript

Atea Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Atea Pharmaceuticals Q1 EPS $(0.57) Beats $(0.59) Estimate

Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10

Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Atea Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Atea Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ...

Atea Pharmaceuticals (NASDAQ:AVIR) Reports Q4 2025 Results as HCV and HEV Pipeline Advance

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

Atea Pharmaceuticals Q4 EPS $(0.57) Misses $(0.53) Estimate

Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.